Hoth Therapeutics, Inc. (HOTH)Healthcare | Biotechnology | New York, United States | NasdaqCM
0.73 USD
-0.01
(-1.776%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.68 -0.05 (-0.049%) ⇩ (April 17, 2026, 7:39 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:51 p.m. EDT
HOTH is currently in a severe downtrend, with the stock price significantly below its 52-week low and showing no signs of stabilization. The negative forward PE and trailing EPS indicate poor financial performance, and the recent price history shows a consistent decline. The recent news of a $2 million raise and positive trial results may offer some optimism, but the stock's fundamentals are weak, and the price-to-book ratio suggests overvaluation. The short-term forecasting model predicts a further decline, which is concerning for short-term traders. Long-term investors should be cautious, as the company's fundamentals are not strong enough to support a buy-and-hold strategy. Dividend investors should avoid this stock, as there are no dividends to speak of. Overall, this is a high-risk investment with no clear momentum or yield. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.151668 |
| AutoARIMA | 0.183239 |
| AutoETS | 0.186059 |
| MSTL | 0.189127 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.064 |
| Excess Kurtosis | -0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.092 |
| Market Cap | 13,963,180 |
| Forward P/E | -1.03 |
| Beta | 0.60 |
| Website | https://hoththerapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.037564754 |
| Address1 | 1,177 Avenue of the Americas |
| Address2 | Suite 5066 5th Floor |
| All Time High | 347.0 |
| All Time Low | 0.489 |
| Ask | 0.7373 |
| Ask Size | 5 |
| Average Daily Volume10 Day | 13,440,060 |
| Average Daily Volume3 Month | 2,723,752 |
| Average Volume | 2,723,752 |
| Average Volume10Days | 13,440,060 |
| Beta | 0.601 |
| Bid | 0.712 |
| Bid Size | 5 |
| Book Value | 0.396 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.73 |
| Current Ratio | 4.724 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.7455 |
| Day Low | 0.6966 |
| Debt To Equity | 0.092 |
| Display Name | Hoth Therapeutics |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 5,626,297 |
| Eps Forward | -0.71 |
| Eps Trailing Twelve Months | -0.9 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.87972 |
| Fifty Day Average Change | -0.14971995 |
| Fifty Day Average Change Percent | -0.17019047 |
| Fifty Two Week Change Percent | -3.7564754 |
| Fifty Two Week High | 2.115 |
| Fifty Two Week High Change | -1.385 |
| Fifty Two Week High Change Percent | -0.6548463 |
| Fifty Two Week Low | 0.489 |
| Fifty Two Week Low Change | 0.24100003 |
| Fifty Two Week Low Change Percent | 0.49284258 |
| Fifty Two Week Range | 0.489 - 2.115 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,550,241,000,000 |
| Float Shares | 15,787,156 |
| Forward Eps | -0.71 |
| Forward P E | -1.028169 |
| Free Cashflow | -5,543,313 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02894 |
| Held Percent Institutions | 0.05163 |
| Implied Shares Outstanding | 19,127,643 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,666,742,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York. |
| Long Name | Hoth Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 13,963,180 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_434856528 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -12,469,302 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,963,179 |
| Number Of Analyst Opinions | 1 |
| Open | 0.7169 |
| Operating Cashflow | -9,803,918 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 646 756 2997 |
| Post Market Change | -0.048600018 |
| Post Market Change Percent | -6.657536 |
| Post Market Price | 0.6814 |
| Post Market Time | 1,776,469,147 |
| Previous Close | 0.7432 |
| Price Hint | 4 |
| Price To Book | 1.8434345 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.301 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0132 |
| Regular Market Change Percent | -1.7761 |
| Regular Market Day High | 0.7455 |
| Regular Market Day Low | 0.6966 |
| Regular Market Day Range | 0.6966 - 0.7455 |
| Regular Market Open | 0.7169 |
| Regular Market Previous Close | 0.7432 |
| Regular Market Price | 0.73 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 889,947 |
| Return On Assets | -1.00885 |
| Return On Equity | -1.91399 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,127,643 |
| Shares Percent Shares Out | 0.0461 |
| Shares Short | 749,807 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,061,221 |
| Short Name | Hoth Therapeutics, Inc. |
| Short Percent Of Float | 0.0477 |
| Short Ratio | 1.88 |
| Source Interval | 15 |
| State | NY |
| Symbol | HOTH |
| Target High Price | 5.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 5.0 |
| Target Median Price | 5.0 |
| Total Cash | 6,247,467 |
| Total Cash Per Share | 0.384 |
| Total Debt | 5,678 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.191785 |
| Two Hundred Day Average Change | -0.46178496 |
| Two Hundred Day Average Change Percent | -0.38747337 |
| Type Disp | Equity |
| Volume | 889,947 |
| Website | https://hoththerapeutics.com |
| Zip | 10,036 |